These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37943834)

  • 1. Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    Rounis K; Makrakis D; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Gourlia K; Xanthopoulos I; Tsamardinos I; Mavroudis D; Agelaki S
    PLoS One; 2023; 18(11):e0294382. PubMed ID: 37943834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Makrakis D; Rounis K; Tsigkas AP; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis I; Agelaki S
    PLoS One; 2023; 18(11):e0294384. PubMed ID: 37943779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    Rounis K; Makrakis D; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Gourlia K; Xanthopoulos I; Tsamardinos I; Mavroudis D; Agelaki S
    PLoS One; 2021; 16(6):e0252537. PubMed ID: 34061904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.